Skip to main content
. 2013 Sep 6;3(9):e145. doi: 10.1038/bcj.2013.44

Figure 6.

Figure 6

Role of patient HLA type in defining LAA IgG responses to K562/GVAX whole-cell vaccine immunotherapy. Molecular HLA typing was obtained from the Clinical Immunogenetics Laboratory of the Johns Hopkins University School of Medicine. The intra-patient variation in the induced IgG responses following vaccination with an identical K562/GVAX whole-cell vaccine product appears likely due not only to prior antigen experience and immunological memory but also to HLA differences between patients. Three examples are highlighted in the figure above; two clinical responders made responses to three of the same antigens (DNAJA1, RPS23 and RHOX). These patients shared both class I (HLA-A*0301) and class II alleles (DRB*1501) in their HLA haplotype. Additionally, 7 of the 19 patients in this study made a response to RHAMM. All had DRB15 and DQB*0602 alleles in their haplotype; indeed 7 of 8 patients with DRB15 and 7 of 7 patients with DQB*0602 in this study made responses to RHAMM. Finally, only two patients made an initial response to the antigen HN1L. They shared an almost identical HLA haplotype (HLA-A*0101, HLA-C*04KBG, HLA-B*035, HLA-DRB*0301 and HLA-DRQ*0201). No other patient in the study had this haplotype.